Abstract
Background/Objectives: Hyponatremia is defined as a serum sodium concentration below 135 mEq/L. It is associated with increased morbidity and mortality. This study aimed to determine the factors associated with mortality in patients hospitalized with moderate to severe hyponatremia in the nephrology clinic and nephrology intensive care unit during an eight-year follow-up period. Methods: This retrospective study included patients admitted between January 2018 and October 2025 who were hospitalized due to moderate or severe hyponatremia. Results: Of 4270 patients, 337 (7.8%) were hospitalized with moderate to severe hyponatremia. The majority of patients were female (60.2%; n = 203). 242 patients (71.8%) had severe hyponatremia. The most common presenting complaint was nausea and vomiting, the most common month and season of presentation was July-Summer, and the most common cause of hyponatremia was drug-induced hyponatremia. The mortality rate was 40.7% (n = 137). The most common cause of death was decompensated heart failure. Factors independently affecting mortality; age (HR = 1.018, 95% CI 1.001–1.037, p = 0.047), malignancy (HR = 2.397, 95% CI 1.459–3.939, p < 0.001), number of hospitalizations (HR = 0.377, 95% CI 0.228–0.623, p < 0.001), EF (HR = 0.972, 95% CI 0.956–0.988, p < 0.001), high phosphorus (HR = 2.397, 95% CI 1.527–3.764, p < 0.001), furosemide use (HR = 1.638, 95% CI 1.018–2.636, p = 0.042) and fluid restriction. Conclusions: Advanced age, malignancy, high phosphorus levels, furosemide use, and fluid restriction were associated with increased mortality, whereas higher ejection fraction and greater number of hospitalizations were protective. These findings emphasize the importance of individualized management strategies and close follow-up in patients with moderate to severe hyponatremia.
1. Introduction
Hyponatremia is defined as a serum sodium concentration below 135 mEq/L []. Its prevalence in hospitalized patients ranges from 15 to 30% [], and is even higher in the elderly population. Hyponatremia is associated with increased morbidity and mortality. Its etiology is broad. Syndrome of inappropriate antidiuretic hormone secretion (SIADH), cirrhosis, renal failure, heart failure, medications, and many other causes can lead to hyponatremia. Diagnosis is crucial because treatment is based on the underlying cause []. Acute severe hyponatremia can lead to seizures, disorientation, psychosis, coma, and even death, whereas chronic and mild hyponatremia presents with symptoms such as nausea, vomiting, headache, and fatigue [].
The primary parameters used to determine the etiology of hyponatremia are volume status, serum and urine osmolality, and urine sodium levels. Additional tests may be necessary for differential diagnosis after these initial assessments [].
Hyponatremia is classified based on serum sodium levels as mild (130–134 mEq/L), moderate (125–130 mEq/L), and severe (<125 mEq/L) []. In a retrospective study by Hao et al. on a general patient population, mortality was found to be higher in patients with hyponatremia compared to those without it. Furthermore, as the severity of hyponatremia increased, so did mortality []. Similarly, in a large cohort from Denmark, hospitalized patients with hyponatremia had significantly higher mortality compared to those with normal sodium levels []. In the said study involving over 50,000 patients, every 1 mmol/L decrease in serum sodium was associated with a 2.3% increase in mortality []. Besides mortality, even a slight reduction in plasma sodium was associated with morbidities such as frailty, attention deficits, sarcopenia, osteoporosis, and cardiac fibrosis [].
In the etiology of hyponatremia, SIADH, heart failure, and medications are among the top causes []. The most common cause is typically the SIADH [].
In this study, at eight years, the etiologies, comorbidities, laboratory findings, season and month of admission, and treatments of patients hospitalized in our clinic due to hyponatremia were compared with their mortality outcomes.
2. Methods
This retrospective cohort study was conducted at the Department of Nephrology, Selçuk University Faculty of Medicine, Konya, Türkiye, between January 2018 and October 2025. The hospital is a tertiary referral center for nephrology cases. Approved by Selçuk University Ethics Committee (No: 2024/18). Informed consent waived due to retrospective design. All procedures followed the Declaration of Helsinki). Data from patient records, including demographic information, comorbidities, medications, treatments received during hospitalization, potential causes of hyponatremia, and laboratory findings, were collected. Mortality data from this eight-year period were retrieved from the national health data registry system (e-Nabiz) of the Ministry of Health of the Republic of Türkiye. Additionally, sodium levels at admission and discharge, season and month of admission, the number of hospitalizations due to hyponatremia, and the duration of hospital stays were recorded. We included in our study retrospectively those who were hospitalized in our clinic for 8 years. Since patients with pseudohyponatremia were already excluded before hospitalization, none of the patients we included in our study were pseudohyponatremic. Exclusion criteria included pseudohyponatremia, mild hyponatremia (Na ≥ 130 mEq/L), missing data, patients lost to follow-up and COVID-19-related hospitalizations (Figure 1).
Figure 1.
Flow diagram of study.
Sodium values corrected based on the patients’ blood glucose measurements were calculated. For every 100 mg/dL increase in serum glucose, 2.4 mEq/L was added to the serum sodium []. Patients with corrected sodium values within the normal range according to hyperglycemia were excluded from the study.
Patients’ comorbidities including diabetes mellitus (DM), hypertension, heart failure, coronary arter disease (CAD), chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), malignancy, presence of pneumonia during hospitalization were questioned and recorded.
Medication use was categorized into diuretics (thiazide and thiazide-like, potassium-sparing, and loop diuretics), antipsychotics, antidepressants, anticonvulsants, angiotensin converting enzyme inhibitor, angiotensin receptor blocker (ACE inhibitors/ARBs), proton pump inhibitor (PPI), chemotherapeutic agents, and other medications.
In clinically euvolemic patients with a serum osmolality below 275 mosm/kg H2O, urine osmolality above 100 mosm/kg, urine sodium of 30 mEq/L, and normal thyroid function tests and cortisol levels, the etiology of hyponatremia was considered to be SIADH. In addition, urinary sodium above 30 mEq/L was considered positive for renal sodium losses [,].
Complete blood count analyses were performed using a Sysmex XN-300 hematology analyzer(Sysmex, Hamburg, Germany). Biochemical parameters, thyroid stimuling hormon (TSH), morning cortisol level (08:00 h), adrenocorticotrophic hormon (ACTH), serum and urine osmolality, and urine sodium were determined with Roche cobas e801 chemistry, freeze-point osmometer and Rocheimmunoassay systems via electrochemiluminesansce method (Roche Diagnostics, Mannheim, Germany). Estimated glomerular filtration rate (eGFR) was calculated and given by the laboratory according to the CKD-EPI formula based on serum creatinine.
Additionally, ejection fraction (EF) and pulmonary artery pressure (PAP) values were recorded for patients who had echocardiography within the last 1 year.
Data from living and deceased patients over the eight-year period were compared to identify factors affecting mortality.
Patients due to COVID-19 were excluded from the study.
2.1. Power Analysis
The sample size was calculated to detect a medium effect (Cohen’s d = 0.5) with a two-sided α = 0.05 and 99% power, requiring at least 148 participants per group.
2.2. Statistical Analysis
All statistical analyses were conducted using the statistical software language R version 4.1.2 (The R Foundation for Statistical Computing, Vienna, Austria; https://www.r-project.org). Before the analyses, the normality of the data was assessed using the Shapiro-Wilk test and Q-Q plots, while the homogeneity of group variances was assessed using the Levene’s test. The findings for numerical variables included in the study were presented as mean ± standard deviation or median with quartiles [1st quartile–3rd quartile], and categorical variables were presented as frequency (n) and percentage. The presence of statistically significant differences in demographic and clinical characteristics, as well as laboratory findings between moderate and severe hyponatremia patients, was evaluated using independent sample t-test, Welch’s I-test, or Mann–Whitney U test. Age, comorbidities, antihypertensive medication use, and the use of hypertonic sodium, fluid restriction, and tolvaptan in treatment were compared among patient groups using Fisher’s exact test and Yates’s correction for continuity (Yates’s chi-squared test). These tests were also used to compare the characteristics of deceased and discharged patients. We used Cox proportional hazard regression model to determine prognostic factors for mortality. Hazard ratios (HR) were presented with 95% confidence intervals. The significance level was taken as 5%.
3. Results
The files of 4270 patients hospitalized in the nephrology clinic over approximately eight years were reviewed. There were 52 recurrent hospitalizations, and the total number of hospitalizations was 389. There were 337 patients hospitalized for moderate to severe hyponatremia (7.8%). Hyponatremia was severe in 242 patients (71.8%). 60.2% (n = 203) of the patients were female. The mean age was 68.1 ± 15.2 years.
The month with the highest number of hospitalizations was July, and the season with the highest number of hospitalizations was summer (p value, respectively p < 0.001 and p = 0.0002).
The mean follow-up period was 590.8 ± 597.7 days (min 1, max 3305 days).
240 patients were excluded from the study due to mild hyponatremia, 18 patients due to incomplete data, 21 patients due to loss of follow-up, and 23 patients with hyponatremia due to COVID-19 positivity.
The most common presenting complaints were nausea and vomiting in 84 patients (25%), weakness in 53 patients (15.8%), dyspnea in 50 patients (14.9%), and confusion in 34 patients (10.1%). The number of patients without any complaints was 20 (6%).
Among comorbidities, hypertension was the most common and was present in 247 patients (73.3%). DM was present in 138 patients (40.8%), CKD in 80 patients (23.7%), CAD in 145 patients (43%), malignancy in 66 patients (19.6%), COPD in 82 patients (24.3%), and pneumonia in 26 patients (7.7%).
The most common causes of hyponatremia in patients were drug-related hyponatremia in 122 patients (36.2%), hypervolemic hyponatremia in 89 patients (27.2%), and SIADH in 74 patients (22.6%).
A total of 337 patients hospitalized with moderate to severe hyponatremia were included in the study, of whom 137 (40.7%) died. The most common causes of death were decompensated heart failure in 52 patients (37.9%), cancer in 33 patients (24%), and sepsis in 27 patients (19.7%).
3.1. Mortality Comparison (Table 1)
Demographic and Clinical Characteristics
The mean age of non-survivors was significantly higher than that of survivors (71.7 ± 14.1 vs. 65.8 ± 15.6 years, p < 0.001). The distribution of sex did not differ significantly between the groups (p = 0.139).
Table 1.
Comparison of Demographic, Clinical, Laboratory, and Treatment Characteristics Between Survivors and Non-Survivors.
Table 1.
Comparison of Demographic, Clinical, Laboratory, and Treatment Characteristics Between Survivors and Non-Survivors.
| Mortality | |||
|---|---|---|---|
| Survivors (n = 200) | Non-Survivors (n = 137) | p-Value | |
| Demographical | |||
| Age (years) | 65.78 ± 15.64 | 71.66 ± 14.09 | <0.001 1 |
| Sex (F/M) | 127/73 | 76/61 | 0.139 2 |
| Admission season | 0.999 2 | ||
| Autumn | 47 (23.5) | 33 824.1) | |
| Spring | 40 (20) | 27 (19.7) | |
| Summer | 70 (35) | 48 (35) | |
| Winter | 43 (21.5) | 29 (21.2) | |
| Comorbidities | |||
| Diabetes mellitus | 80 (40) | 58 (42.3) | 0.668 2 |
| Hypertension | 150 (75) | 97 (70.8) | 0.392 2 |
| CKD | 44 (22) | 36 (26.3) | 0.365 2 |
| CAD | 77 (38.5) | 68 (49.6) | 0.043 2 |
| Malignity | 22 (11) | 44 (32.4) | <0.001 2 |
| COPD | 49 (24.5) | 33 (24.1) | 0.931 2 |
| Pneumonia | 11 (5.5) | 15 (10.9) | 0.102 3 |
| No. of hospitalization | 1.96 (0 to 18) | 1.18 (1 to 3) | 0.005 4 |
| Length of stay (days) | 6.67 (1 to 25) | 9.73 (1 to 43) | <0.001 4 |
| EF | 58 (18 to 68) | 55 (10 to 65) | <0.001 4 |
| PAP | 32.5 (18 to 72) | 40 (20 to 73) | 0.086 4 |
| Drugs | |||
| Thiazide diuretic use | 82 (41) | 46 (33.6) | 0.168 2 |
| Antidepressive-antiepileptic | 59 (29.5) | 36 (26.3) | 0.518 2 |
| ACEi/ARB use | 97 (48.5) | 62 (45.3) | 0.558 2 |
| Spiranolactone | 27 (13.5) | 41 (29.9) | <0.001 2 |
| Furosemide | 27 (13.6) | 47 (34.3) | <0.001 2 |
| Chemotherapy | 16 (8) | 30 (21.9) | <0.001 2 |
| Other drugs | 171 (85.5) | 118 (86.1) | 0.871 2 |
| Glucose (72–106 mg/dL) | 118 [97–141.25] | 121 [100–158] | 0.282 4 |
| High glucose | 143 (71.5) | 102 (74.5) | 0.550 2 |
| Urea nitrogen (16.6–48.5 mg/dL) | 42 [24.5–84] | 60 [37–130] | <0.001 4 |
| High urea | 86 (43) | 81 (59.1) | 0.004 2 |
| Creatinine (0.5–0.9 mg/dL) | 1.02 [0.70–1.87] | 1.25 [0.84–2.32] | 0.015 4 |
| High creatinine | 98 (49) | 85 (62) | 0.018 2 |
| eGFR (ml/min/1.73 m2) | 72.55 [32.35–97.40] | 55 [28–87.5] | 0.011 4 |
| Admission Sodium (135–145 mEq/L) | 122 [117.75–125] | 122 [118–126] | 0.603 4 |
| Discharge Sodium (135–145 mEq/L) | 134 [132–136] | 134 [132–137] | 0.775 4 |
| Low discharge sodium | 115 (57.5) | 74 (54) | 0.527 2 |
| Potassium (3.5–5.1 mmol/L) | 4.27 [3.79–4.88] | 4.49 [3.94–5.30] | 0.007 4 |
| High potassium | 54 (27) | 57 (41.6) | 0.005 2 |
| Calcium (8.6–10.5 mg/dL) | 8.80 [8.38–9.30] | 8.80 [8.20–9.20] | 0.310 5 |
| Low calcium | 67 (33.5) | 59 (43.1) | 0.075 2 |
| Magnesium (1.62.6 mg/dL) | 1.74 [1.57–1.95] | 1.84 [1.61–2.11] | 0.027 4 |
| Low magnesium | 83 (41.5) | 57 (41.6) | 0.985 2 |
| Phosphorus (2.5–4.5 mg/dL) | 3.30 [2.90–4.30] | 3.50 [2.90–3.80] | 0.090 4 |
| High phosphorus | 42 (21) | 43 (31.4) | 0.031 2 |
| Albumin (3.5–5.2 gr/dL) | 3.76 ± 0.55 | 3.40 ± 0.63 | <0.001 1 |
| Low albumin | 81 (40.5) | 75 (54.7) | 0.010 2 |
| Uric acid (2.4–5.7 mg/dL) | 5.25 [3.38–7.23] | 6.30 [4.10–8.20] | 0.005 4 |
| High uric acid | 90 (45) | 72 (52.6) | 0.173 2 |
| TSH (0.27–4.2 µIU/mL) | 1.36 [0.81–2.28] | 1.48 [0.80–2.33] | 0.870 4 |
| Cortisol (6.2–19.4 µg(dL) | 15.10 [11.40–19.70] | 15.45 [12–20.08] | 0.471 4 |
| ACTH (7.2–63.3 pg/mL) | 25.50 [14.07–45.88] | 24.80 [15–43.60] | 0.968 4 |
| Urine osmolality (50–1200 mosm/kgH2O) | 382.75 ± 150.82 | 394.20 ± 164.96 | 0.721 1 |
| Urine sodium (mEq/L) | 49.50 [30–70.25] | 49 [29–88] | 0.443 4 |
| High urine sodium (>20 mEq/L) | 43 (26.2) | 25 (26.9) | 0.908 2 |
| Serum osmolality (275–285 mosm/kgH2O) | 270 [265–278] | 273 [259–290] | 0.362 4 |
| Treatment | |||
| High hypertonic sodium | 161 (80.5) | 100 (73) | 0.105 2 |
| Fluid restriction | 84 (42) | 84 (61.3) | <0.001 2 |
| Tolvaptan | 14 (7) | 9 (6.6) | >0.999 3 |
1 student’s t-test; 2 Pearson chi-square test; 3 Chi-square with Yates continuity correction; 4 Mann-Whitney U test; 5 student’s t-test. Abbreviations: CKD, chronic kidney disease; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; PAP, pulmonary artery pressure; EF, ejection fraction. p < 0.05 are written in bold.
3.2. Comorbidities
Among comorbid conditions, the prevalence of coronary artery disease (CAD) (p = 0.043) and malignancy (p < 0.001) was significantly higher in non-survivors. Other chronic comorbidities such as diabetes mellitus (DM), hypertension, chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), and pneumonia did not differ significantly between groups (p > 0.05).
3.3. Hospitalization Parameters
Non-survivors had a longer length of hospital stay (median = 9.7 days, range 1–43) compared to survivors (median = 6.7 days, range 1–25) (p < 0.001). The number of previous hospitalizations was also lower among non-survivors (p = 0.005).
3.4. Medication Use
The use of aldosterone antagonists (spironolactone) (p < 0.001), furosemide (p < 0.001), and chemotherapy (p < 0.001) was significantly more frequent in non-survivors. No significant differences were observed regarding thiazide diuretics, anticonvulsants, ACE inhibitors/ARBs, or other medications (p > 0.05).
3.5. Laboratory Findings
Non-survivors had significantly higher serum urea (p < 0.001), creatinine (p = 0.015), potassium (p = 0.007), magnesium (p = 0.027), uric acid (p = 0.005*), and phosphorus (p = 0.031) levels, and lower estimated glomerular filtration rate (eGFR) (p = 0.011) and serum albumin concentrations (p < 0.001).
Categorical analysis showed that the proportion of patients with elevated urea (59.1% vs. 43.0%; p = 0.004), elevated creatinine (62.0% vs. 49.0%; p = 0.018), elevated potassium (41.6% vs. 27.0%; p = 0.005), elevated phosphorus (31.4% vs. 21.0%; p = 0.031), and low albumin (54.7% vs. 40.5%; p = 0.010) was significantly greater among non-survivors.
Admission and discharge sodium levels did not differ significantly between survivors and non-survivors (p > 0.05). Similarly, no significant group differences were observed for serum calcium, TSH, cortisol, ACTH, urine or serum osmolality (p > 0.05).
3.6. Treatment Characteristics
Fluid restriction was applied significantly more often in non-survivors than in survivors (61.3% vs. 42.0%; p < 0.001). The frequency of hypertonic saline use and tolvaptan treatment did not differ significantly between groups (p > 0.05).
In the univariate Cox regression analysis, increased age increased the risk of death (HR = 1.021, 95% CI 1.008–1.034, p < 0.001). Among comorbidities, the presence of coronary artery disease (CAD) (HR = 1.461, 95% CI 1.045–2.044, p = 0.026) and malignancy (HR = 2.685, 95% CI 1.865–3.864, p < 0.001) were significantly related to higher mortality. A lower number of hospitalizations (HR = 0.642, 95% CI 0.472–0.874, p = 0.004) and reduced ejection fraction (EF) (HR = 0.99, 95% CI 0.955–0.983, p < 0.001) were also associated with increased mortality risk (Table 2).
Table 2.
Univariate and Multiple Cox Proportional Hazards Models Identifying Independent Predictors of In-Hospital Mortality.
Regarding laboratory parameters, elevated urea (HR = 1.005, p < 0.001), creatinine (HR = 1.089, p = 0.007), phosphorus (HR = 1.675, p = 0.005), potassium (HR = 1.267, p < 0.001), and uric acid (HR = 1.073, p = 0.008) levels were significantly associated with higher mortality, whereas lower albumin levels also increased the risk (HR = 1.532, p = 0.013). In addition, use of furosemide (HR = 2.228, p < 0.001) and fluid restriction (HR = 1.960, p < 0.001) were predictors of poor prognosis (Table 2).
In the multivariate model, after adjustment for confounding factors, age (HR = 1.018, 95% CI 1.001–1.037, p = 0.047), malignancy (HR = 2.397, 95% CI 1.459–3.939, p < 0.001), number of hospitalizations (HR = 0.377, 95% CI 0.228–0.623, p < 0.001), EF (HR = 0.972, 95% CI 0.956–0.988, p < 0.001), high phosphorus (HR = 2.397, 95% CI 1.527–3.764, p < 0.001), furosemide use (HR = 1.638, 95% CI 1.018–2.636, p = 0.042), and fluid restriction (HR = 2.160, 95% CI 1.350–3.450, p = 0.001) remained independent predictors of mortality (Table 2, Figure 2).
Figure 2.
Kaplan–Meier Curves for Overall Survival According to Clinical and Biochemical Factors. Panels show overall survival stratified by (A) presence of malignancy, (B) use of furosemide, (C) serum phosphorus level, and (D) fluid restriction therapy. Shaded areas indicate 95% confidence intervals. The number of patients at risk is shown below each curve.
4. Discussion
There are many causes of hyponatremia, with the most common being known as SIADH [,]. In this study, the three most common causes identified drug-related hyponatremia, hypervolemic hyponatremia and SIADH. In patients with hyponatremia, the etiology does not always involve a single cause. These patients usually have multiple comorbidities and use several medications. Therefore, it is not easy to determine the etiology precisely. A study involving patients with severe hyponatremia found that 44% of patients had multifactorial etiology []. We evaluated the patient’s complaint, physical examination findings and laboratory findings together and evaluated the ‘most probable’ cause as the cause of hyponatremia. However, even in medication-induced cases, other accompanying factors (such as drugs causing SIADH) might also have contributed to hyponatremia. A 10-year pharmacovigilance study by Ramirez et al. also showed that drugs are the most common cause of severe hyponatremia []. The majority of our patient group had severe hyponatremia. In a 5-year retrospective study published by Becerre Anez and colleagues in 2025, thiazide-associated hyponatremia was the most common hyponatremia []. In this respect, our study parallels these studies. The reason why drug-related hyponatremia was the most common cause in these two recent studies and in our study may be that the development of patient data and record systems in recent years, the medications used by patients can be easily accessed, and the tendency to use thiazide as part of antihypertensive treatment has increased.
Additionally, hypervolemic hyponatremia was the second most common cause in our study. This may be due to the habit in our center of referring patients with right or left heart failure to Nephrology when there is concomitant renal function loss or electrolyte disturbance. This approach is not limited to our center []. In the study conducted by Ternero-Vega and colleagues in Spain, where they evaluated hyponatremic patients according to their volume status, hypervolemic hyponatremia was seen most frequently, although the rates were close to each other [].
Although hyponatremia is known to increase mortality, the number of studies focusing solely on patients with hyponatremia is quite limited. In a study by Mustajoki et al., which included patients with severe hyponatremia (serum Na < 116 mEq/L) presenting to the emergency department, the 1-year mortality was found to be 18% []. Another retrospective study reported a 1-year mortality of 22% in severe hyponatremia []. In our study, we found the mortality rate to be 40.7%. The longer follow-up period (8 years) in our study might be a possible reason for the higher mortality rate. Furthermore, it is unlikely that moderate-severe hyponatremia will occur alone in a patient without comorbidities or multiple medication use. The high prevalence of comorbidities affecting many vital organs, such as hypertension, DM, CAD, CKD, COPD, and malignancy in our patient group, may be a contributing factor to the high mortality rate.
In this study, the causes of death were decompensated heart failure in 52 patients (37.9%), cancer in 33 patients (24%), and sepsis in 27 patients (19.7%). Hyponatremia is known to be an important mortality indicator in decompensated heart failure. In the meta-analysis by Zhao et al., it was shown that 1-year mortality was higher in patients with heart failure []. We could not find a study showing the causes of long-term mortality in patients hospitalized primarily with hyponatremia. However, we can assume that the relationship between heart failure mortality and hyponatremia is two-way.
There are studies suggesting that mortality increases as the severity of hyponatremia increases [,]. However, the effect of lower sodium levels and more severe hyponatremia on mortality is not always linear or independent. For example, in a large Danish cohort, no greater mortality was found in the sodium <120 mmol/L group than expected []. In our study, we did not find a relationship between the severity of hyponatremia and mortality. Al Yaqoubi et al., like us, did not find a relationship between 1-year mortality and severity of hyponatremia []. They considered the reason as single-center. It is probably not sodium level alone but the underlying disease severity and comorbidity burden that stand out as the main factors driving mortality.
In this study, the month with the highest number of hospitalizations was July, and the season with the highest number of hospitalizations was summer. This is also consistent with studies in the literature [,].
The clinical symptoms of hyponatremia typically result from brain edema. Early symptoms include nausea and vomiting, while late symptoms include lethargy, seizures, stupor, and coma []. In our study, the most common presenting complaints of patients were nausea and vomiting.
In this study, we found that mortality was significantly higher in patients with CAD, one of the comorbidities. Additionally, deceased patients had lower ejection fraction. In the meta-analysis of the Meta-Analysis Global Group in Chronic heart failure (MAGGIC) involving patients with preserved EF and reduced EF, both preserved and reduced EF patients with hyponatremia had higher in-hospital mortality []. Similarly, another study in France found that low sodium levels in heart failure patients were associated with increased mortality []. In a study evaluating in-hospital mortality in hyponatremic patients, mortality was found to be higher in patients with hypervolemic hyponatremia and heart failure []. In our study, mortality was also higher in this patient group after 8 years of follow-up. The rate of furosemide use was higher in our patients who died during follow-up. The fact that the profile of deceased patients included those with heart failure, and the higher use of furosemid in these patients is considered a possible reason for this outcome. In this study, when multiple Cox regression analysis was performed, we found that furosemide use was still associated with mortality. In our study, mortality was more common in patients who underwent fluid restriction. The patients who underwent fluid restriction were hypervolemic and had malignant SIADH. Therefore, the relationship between mortality and the patients’ hypervolemia and malignancy, rather than the fluid restriction itself, is more likely to be related to mortality.
We found that malignancy was also a mortality-related factor in patients hospitalized with hyponatremia. This is an expected finding and has been supported by studies [,].
In this study, we found hyperphosphatemia to be an independent predictor of increased mortality in the moderate and severe hyponatremia population. Phosphorus intake can be affected by many factors, including loss of renal function, nutrition, malignancy, and medications. The patients in our study had a high number of comorbidities and, therefore, were taking multiple medications. Shuto et al. demonstrated in their study that elevated phosphorus levels cause endothelial damage []. In a study conducted in patients with subarachnoid hemorrhage, hyperphosphatemia was also found to be associated with increased mortality []. In a recent study of a large cohort of patients undergoing cardiac surgery, hyperphosphatemia was significantly associated with prolonged intubation, prolonged hospital stay, and increased hospital mortality [].
The limitations of our study are its single-center design and retrospective nature. We are of the opinion that our study is significant as it focuses solely on hyponatremic patients and evaluates clinical and laboratory parameters effective on mortality of hyponatremic patients over a long follow-up period. The majority of the current studies compare hyponatremic patients with non-hyponatremic patients from general patient population. We only included patients with moderate to severe hyponatremia who were hospitalized and examined and treated. This study examines the long-term follow-up of hyponatremic patients from the perspective and approach of a nephrologist. Furthermore, its comprehensive analysis of the patients’ medications, including the season and month of admission, is a key feature of this study. Also, our follow up period is long. We believe that these are an advantage for our study.
5. Conclusions
In conclusion, we have confirmed that hyponatremia is more common in older age and female gender. We can say that medications have come to the forefront in this study, along with recent studies on the etiology of hyponatremia. Furthermore, we can say that advanced age, heart failure, and malignancy are the leading causes of mortality in these patients. We should not ignore the contribution of high phosphorus levels to mortality. These theories should be supported by more and more comprehensive studies on hyponatremia, the most common electrolyte disorder.
Author Contributions
Y.C.Y. (writing, data collection, statistical analysis), Z.B. (data entry), M.K.K. (statistical analysis), M.Z.K. (data collection), L.A. (reviewing). All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
The study was conducted in accordance with the Declaration of Helsinki, and approved by the Selçuk University Ethics Committee (protocol code No: 2024/18 and 2 January 2024 of approval).
Informed Consent Statement
Informed consent waived due to retrospective design.
Data Availability Statement
Dataset splitting upon request from authors.
Conflicts of Interest
The authors have declared that no conflict of interest exists. No financial support was received.
References
- Adrogué, H.J.; Madias, N.E. Hyponatremia. N. Engl. J. Med. 2000, 342, 1581–1589. [Google Scholar] [CrossRef] [PubMed]
- Upadhyay, A.; Jaber, B.L.; Madias, N.E. Incidence and prevalence of hyponatremia. Am. J. Med. 2006, 119 (Suppl. S1), S30–S35. [Google Scholar] [CrossRef]
- Braun, M.M.; Barstow, C.H.; Pyzocha, N.J. Diagnosis and management of sodium disorders: Hyponatremia and hypernatremia. Am. Fam. Physician 2015, 91, 299–307. [Google Scholar]
- Peri, A. Morbidity and mortality of hyponatremia. Front. Horm. Res. 2019, 52, 36–48. [Google Scholar]
- Corona, G.; Giuliani, C.; Verbalis, J.G.; Forti, G.; Maggi, M.; Peri, A. Hyponatremia improvement is associated with a reduced risk of mortality: Evidence from a meta-analysis. PLoS ONE 2015, 10, e0124105. [Google Scholar] [CrossRef]
- Verbalis, J.G.; Goldsmith, S.R.; Greenberg, A.; Korzelius, C.; Schrier, R.W.; Sterns, R.H.; Thompson, C.J. Diagnosis, evaluation, and treatment of hyponatremia: Expert panel recommendations. Am. J. Med. 2013, 126 (Suppl. S1), S1–S42. [Google Scholar] [CrossRef]
- Hao, J.; Li, Y.; Zhang, X.; Pang, C.; Wang, Y.; Nigwekar, S.U.; Qiu, L.; Chen, L. The prevalence and mortality of hyponatremia is seriously underestimated in Chinese general medical patients: An observational retrospective study. BMC Nephrol. 2017, 18, 328. [Google Scholar] [CrossRef]
- Holland-Bill, L.; Christiansen, C.F.; Heide-Jørgensen, U.; Ulrichsen, S.P.; Ring, T.; Jørgensen, J.O.; Sørensen, H.T. Hyponatremia and mortality risk: A Danish cohort study of 279,508 acutely hospitalized patients. Eur. J. Endocrinol. 2015, 173, 71–81. [Google Scholar] [CrossRef]
- Wald, R.; Jaber, B.L.; Price, L.L.; Upadhyay, A.; Madias, N.E. Impact of hospital-associated hyponatremia on selected outcomes. Arch. Intern. Med. 2010, 170, 294–302. [Google Scholar] [CrossRef]
- Ghosal, A.; Qadeer, H.A.; Nekkanti, S.K.; Pradhan, P.; Okoye, C.; Waqar, D. A conspectus of euvolemic hyponatremia, its various etiologies, and treatment modalities: A comprehensive review of the literature. Cureus 2023, 15, e43390. [Google Scholar] [CrossRef]
- Voets, P. Examining the significance of arginine vasopressin release to elucidate the often multifactorial etiology of hypotonic hyponatremia: A novel criterion. Physiol. Rep. 2024, 12, e15967. [Google Scholar] [CrossRef] [PubMed]
- Spasovski, G.; Vanholder, R.; Allolio, B.; Annane, D.; Ball, S.; Bichet, D.; Decaux, G.; Fenske, W.; Hoorn, E.J.; Ichai, C.; et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur. J. Endocrinol. 2014, 170, G1–G47. [Google Scholar] [CrossRef] [PubMed]
- Hoorn, E.J.; Zietse, R. Diagnosis and treatment of hyponatremia: Compilation of the guidelines. J. Am. Soc. Nephrol. 2017, 28, 1340–1349. [Google Scholar] [CrossRef]
- Dineen, R.; Thompson, C.J.; Sherlock, M. Hyponatraemia—Presentations and management. Clin. Med. 2017, 17, 263–269. [Google Scholar] [CrossRef]
- Warren, A.M.; Grossmann, M.; Christ-Crain, M.; Russell, N. Syndrome of inappropriate antidiuresis: From pathophysiology to management. Endocr. Rev. 2023, 44, 819–861. [Google Scholar] [CrossRef]
- Kwon, S.; Kim, H.; Lee, J.; Shin, J.; Kim, S.H.; Hwang, J.H. Thiazide-associated hyponatremia in arterial hypertension patients: A nationwide population-based cohort study. J. Hypertens. 2024, 42, 123–133. [Google Scholar] [CrossRef]
- Mustajoki, S. Severe hyponatraemia (P-Na < 116 mmol/L) in the emergency department: A series of 394 cases. Intern. Emerg. Med. 2023, 18, 781–789. [Google Scholar]
- Ramírez, E.; Rodríguez, A.; Queiruga, J.; García, I.; Díaz, L.; Martínez, L.; Muñoz, R.; Muñoz, M.; Tong, H.Y.; Martínez, J.C.; et al. Severe hyponatremia is often drug induced: 10-year results of a prospective pharmacovigilance program. Clin. Pharmacol. Ther. 2019, 106, 1362–1379. [Google Scholar] [CrossRef]
- Becerra Añez, K.M.; Sánchez Juan, C.; Artero Fullana, A.; Jiménez Portilla, A.; Ferrer García, J.C. Sodium evolution in hyponatremia: A retrospective analysis in a tertiary care center. Endocrinol. Diabetes Nutr. 2025, 72, 501563. [Google Scholar] [CrossRef]
- Rondon, H.; Badireddy, M. Hyponatremia. In StatPearls [Internet]; StatPearls Publishing: Treasure Island, FL, USA, 2025. Available online: https://www.ncbi.nlm.nih.gov/books/NBK470386/ (accessed on 14 June 2023).
- Ternero-Vega, J.E.; Jiménez-de-Juan, C.; Castilla-Yelamo, J.; Cantón-Habas, V.; Sánchez-Ruiz-Granados, E.; Barón-Ramos, M.; Ropero-Luis, G.; Gómez-Salgado, J.; Bernabeu-Wittel, M. Impact of hyponatremia in patients hospitalized in internal medicine units. Medicine 2024, 103, e38312. [Google Scholar] [CrossRef]
- Waikar, S.S.; Mount, D.B.; Curhan, G.C. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am. J. Med. 2009, 122, 857–865. [Google Scholar] [CrossRef]
- Zhao, W.; Qin, J.; Lu, G.; Wang, Y.; Qiao, L.; Li, Y. Association between hyponatremia and adverse clinical outcomes of heart failure: Current evidence based on a systematic review and meta-analysis. Front. Cardiovasc. Med. 2023, 10, 1339203. [Google Scholar] [CrossRef]
- Akirov, A.; Diker-Cohen, T.; Steinmetz, T.; Amitai, O.; Shimon, I. Sodium levels on admission are associated with mortality risk in hospitalized patients. Eur. J. Intern. Med. 2017, 46, 25–29. [Google Scholar] [CrossRef]
- Ryoo, J.; Choi, A.; Cho, H.; Bae, W. Relationship of severity of hyponatremia and adverse outcomes in children visiting the emergency department. Front. Pediatr. 2024, 12, 1379727. [Google Scholar] [CrossRef]
- Al Yaqoubi, I.H.; Al-Maqbali, J.S.; Al Farsi, A.A.; Al Jabri, R.K.; Khan, S.A.; Al Alawi, A.M. Prevalence of hyponatremia among medically hospitalized patients and associated outcomes: A retrospective cohort study. Ann. Saudi Med. 2024, 44, 339–348. [Google Scholar] [CrossRef]
- Kutz, A.; Ebrahimi, F.; Sailer, C.O.; Wagner, U.; Schuetz, P.; Mueller, B.; Christ-Crain, M. Seasonality of hypoosmolar hyponatremia in medical inpatients: Data from a nationwide cohort study. J. Clin. Endocrinol. Metab. 2020, 105, dgz320. [Google Scholar] [CrossRef] [PubMed]
- Nicholls, T.; Hoermann, R.; Wootton, E.; Mansouri, N.; Stevens, M.; Vo, H.; Grossmann, M.; Warren, A.M. Increased ambient temperature and hyponatremia presentations: A 10-year retrospective study at an Australian hospital. J. Clin. Endocrinol. Metab. 2025, 110, e2666–e2673. [Google Scholar] [CrossRef] [PubMed]
- Sterns, R.H. Disorders of plasma sodium—Causes, consequences, and correction. N. Engl. J. Med. 2015, 372, 55–65. [Google Scholar] [CrossRef]
- Rusinaru, D.; Tribouilloy, C.; Berry, C.; Richards, A.M.; Whalley, G.A.; Earle, N.; Poppe, K.K.; Guazzi, M.; Macin, S.M.; Komajda, M.; et al. Relationship of serum sodium concentration to mortality in a wide spectrum of heart failure patients with preserved and with reduced ejection fraction: An individual patient data meta-analysis. Eur. J. Heart Fail. 2012, 14, 1139–1146. [Google Scholar] [CrossRef] [PubMed]
- Tribouilloy, C.; Rusinaru, D.; Mahjoub, H.; Soulière, V.; Lévy, F.; Peltier, M.; Slama, M.; Massy, Z. Prognosis of heart failure with preserved ejection fraction: A five-year prospective population-based study. Eur. Heart J. 2008, 29, 339–347. [Google Scholar] [CrossRef]
- Singh, P.; Arora, S.; Singh, D.; Kalra, S.; Singh, A.; Arora, U.; Mittal, N.; Goyal, M.K.; Kaur, S.; Kalra, E. Hyponatremia and outcome: Is severity more important than etiology? Cureus 2023, 15, e42808. [Google Scholar] [CrossRef]
- Yoon, J.; Ahn, S.H.; Lee, Y.J.; Kim, C.M. Hyponatremia as an independent prognostic factor in patients with terminal cancer. Support. Care Cancer 2015, 23, 1735–1740. [Google Scholar] [CrossRef]
- Shuto, E.; Taketani, Y.; Tanaka, R.; Harada, N.; Isshiki, M.; Sato, M.; Nashiki, K.; Amo, K.; Yamamoto, H.; Higashi, Y.; et al. Dietary phosphorus acutely impairs endothelial function. J. Am. Soc. Nephrol. 2009, 20, 1504–1512. [Google Scholar] [CrossRef]
- Wang, R.; Zhang, J.; Xu, J.; He, M. Association between serum phosphate level and mortality of patients with aneurysmal subarachnoid hemorrhage. Neurosurg. Rev. 2024, 47, 891. [Google Scholar] [CrossRef]
- Steck, D.T.; Mostofi, N.; Togashi, K.; Li, R.; Wu, D.; Wells, L.; Fong, C.T.; Tillinghast, K.; O’Reilly-Shah, V.N.; Jelacic, S. Clinical outcomes in patients with phosphate abnormalities after cardiac surgery: A retrospective cohort study. Anesth. Analg. 2025, 140, 938–946. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).